CCSJ137X2201 A First-in-Human, Two-Part (Open Label, and Randomized/Bouble Blind/Placebo Controlled), Single- and Repeat-Dose Study of CSJ137 in Erythropoietin-Treated Chronic Hemodialysis Patients with Functional Iron-Deficiency Anemia

Project: Research project

StatusActive
Effective start/end date10/9/173/15/20

Funding

  • Novartis Pharmaceuticals Corporation (CCSJ137X2201)